Henry M. Marshall

Henry M. Marshall

Auto-generated profile, based on publicly available information

Henry M. Marshall

University of Queensland Thoracic Research Centre and Department of Thoracic Medicine, The Prince Charles Hospital, Chermside, Queensland, Australia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2018 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
TFThomas W. Ferkol
Thomas W. Ferkol
HFHarold J. Farber
Harold J. Farber
STEFANIA La GruttaSTEFANIA La Grutta
STEFANIA La Grutta
FLFrank T. Leone
Frank T. Leone
HMHenry M. Marshall
Henry M. Marshall
DSDean E. Schraufnagel
Dean E. Schraufnagel
Children and adolescents are highly susceptible to nicotine addiction, which affects their brain development, even in those who smoke infrequently. Young people who become addicted to nicotine are at greater risk of becoming lifelong tobacco consumers. The use of nicotine-delivering electronic cigarettes has risen dramatically among youths worldwide. In addition to physical dependence, adolescents are susceptible to social and environmental influences to use electronic cigarettes. The product design, flavours, marketing, and perception of safety and acceptability have increased the appeal of electronic cigarettes to young people, thus leading to new generations addicted to nicotine. Moreover, there is growing evidence that electronic cigarettes in children and adolescents serve as a gateway to cigarette smoking. There can be no argument for harm reduction in children. To protect this vulnerable population from electronic cigarettes and other nicotine delivery devices, we recommend that electronic cigarettes be regulated as tobacco products and included in smoke-free policies. Sale of electronic cigarettes should be barred to youths worldwide. Flavouring should be prohibited in electronic cigarettes, and advertising accessible by youths and young adults be banned. Finally, we recommend greater research on the health effects of electronic cigarettes and surveillance of use across different countries.

1 December 2013
Verified
Journal Article
Open access
PDF file
Nico Van ZandwijkNico Van Zandwijk
Nico Van Zandwijk
CCChristopher Clarke
Christopher Clarke
DHDouglas Henderson
Douglas Henderson
AMA. William Musk
A. William Musk
KFKwun Fong
Kwun Fong
APAndrew Penman
Andrew Penman
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma

21 April 2017 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
MWMarianne Weber
Marianne Weber
SYSarsha Yap
Sarsha Yap
DGDavid Goldsbury
David Goldsbury
DMDavid Manners
David Manners
MTMartin Tammemagi
Martin Tammemagi
KCKaren Canfell
Karen Canfell

1 April 2020 in Annals of the American Thoracic Society
Verified
Journal Article
Open access
KLKuan Pin Lim
Kuan Pin Lim
HMHenry Marshall
Henry Marshall
MTMartin Tammemägi
Martin Tammemägi
FBFraser Brims
Fraser Brims
AMAnnette McWilliams
Annette McWilliams
SLStephen Lam
Stephen Lam
Rationale: The NLST (National Lung Screening Trial) reported a 20% reduction in lung cancer mortality with low-dose computed tomography screening; however, important questions on how to optimize screening remain, including which selection criteria are most accurate at detecting lung cancers and what nodule management protocol is most efficient. The PLCOm2012 (Prostate, Lung, Colorectal and Ovarian) Cancer Screening Trial 6-year and PanCan (Pan-Canadian Early Detection of Lung Cancer) nodule malignancy risk models are two of the better validated risk prediction models for screenee selection and nodule management, respectively. Combined use of these models for participant selection and nodule management could significantly improve screening efficiency. Objectives: The ILST (International Lung Screening Trial) is a prospective cohort study with two primary aims: 1) Compare the accuracy of the PLCOm2012 model against U.S. Preventive Services Task Force (USPSTF) criteria for detecting lung cancers and 2) evaluate nodule management efficiency using the PanCan nodule probability calculator-based protocol versus Lung-RADS. Methods: ILST will recruit 4,500 participants who meet USPSTF and/or PLCOm2012 risk ≥1.51%/6-year selection criteria. Participants will undergo baseline and 2-year low-dose computed tomography screening. Baseline nodules are managed according to PanCan probability score. Participants will be followed up for a minimum of 5 years. Primary outcomes for aim 1 are the proportion of individuals selected for screening, proportion of lung cancers detected, and positive predictive values of either selection criteria, and outcomes for aim 2 include comparing distributions of individuals and the proportion of lung cancers in each of three management groups: next surveillance scan, early recall scan, or diagnostic evaluation recommended. Statistical powers to detect differences in the four components of primary study aims were ≥82%. Conclusions: ILST will prospectively evaluate the comparative accuracy and effectiveness of two promising multivariable risk models for screenee selection and nodule management in lung cancer screening. Clinical trial registered with www.clinicaltrials.gov (NCT02871856).

16 November 2020 in Respirology
Verified
Journal Article
Open access
PDF file
NRNicole Rankin
Nicole Rankin
AMAnnette McWilliams
Annette McWilliams
HMHenry M. Marshall
Henry M. Marshall
Lung cancer is the number one cause of cancer death worldwide. The benefits of lung cancer screening to reduce mortality and detect early‐stage disease are no longer in any doubt based on the results of two landmark trials using LDCT. Lung cancer screening has been implemented in the US and South Korea and is under consideration by other communities. Successful translation of demonstrated research outcomes into the routine clinical setting requires careful implementation and co‐ordinated input from multiple stakeholders. Implementation aspects may be specific to different healthcare settings. Important knowledge gaps remain, which must be addressed in order to optimize screening benefits and minimize screening harms. Lung cancer screening differs from all other cancer screening programmes as lung cancer risk is driven by smoking, a highly stigmatized behaviour. Stigma, along with other factors, can impact smokers' engagement with screening, meaning that smokers are generally ‘hard to reach’. This review considers critical points along the patient journey. The first steps include selecting a risk threshold at which to screen, successfully engaging the target population and maximizing screening uptake. We review barriers to smoker engagement in lung and other cancer screening programmes. Recruitment strategies used in trials and real‐world (clinical) programmes and associated screening uptake are reviewed. To aid cross‐study comparisons, we propose a standardized nomenclature for recording and calculating recruitment outcomes. Once participants have engaged with the screening programme, we discuss programme components that are critical to maximize net benefit. A whole‐of‐programme approach is required including a standardized and multidisciplinary approach to pulmonary nodule management, incorporating probabilistic nodule risk assessment and longitudinal volumetric analysis, to reduce unnecessary downstream investigations and surgery; the integration of smoking cessation; and identification and intervention for other tobacco related diseases, such as coronary artery calcification and chronic obstructive pulmonary disease. National support, integrated with tobacco control programmes, and with appropriate funding, accreditation, data collection, quality assurance and reporting mechanisms will enhance lung cancer screening programme success and reduce the risks associated with opportunistic, ad hoc screening. Finally, implementation research must play a greater role in informing policy change about targeted LDCT screening programmes.

1 April 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
JHJoseph K. Hwang
Joseph K. Hwang
BPBarbara J. Page
Barbara J. Page
DFDavid Flynn
David Flynn
LPLinda Passmore
Linda Passmore
EMElizabeth McCaul
Elizabeth McCaul
KFKwun M. Fong
Kwun M. Fong